Comprehensive Stock Comparison
Compare Molecular Partners AG (MOLN) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | REGN | 1.0% revenue growth vs MOLN's -29.4% |
| Quality / Margins | REGN | 31.4% net margin vs MOLN's -10.9% |
| Stability / Safety | MOLN | Beta 0.20 vs REGN's 0.58, lower leverage |
| Dividends | REGN | 0.4% yield; 1-year raise streak; MOLN pays no meaningful dividend |
| Momentum (1Y) | REGN | +12.4% vs MOLN's -0.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs MOLN's -53.7%, ROIC 12.4% vs -47.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Molecular Partners is a clinical-stage biopharmaceutical company that develops targeted protein therapeutics using its proprietary DARPin platform technology. It generates revenue primarily through research collaborations and licensing deals with pharmaceutical partners — including Novartis, Amgen, and AbbVie — which provide upfront payments, milestone payments, and potential future royalties. The company's key competitive advantage is its DARPin platform, which enables the creation of multi-specific protein therapeutics with high target specificity and modular design capabilities.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). MOLN leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
REGN and MOLN operate at a comparable scale, with $14.3B and $0 in trailing revenue. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to MOLN's -10.9%. On growth, REGN holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.3B |
| EBITDAEarnings before interest/tax | -$58M | $4.2B |
| Net IncomeAfter-tax profit | -$60M | $4.5B |
| Free Cash FlowCash after capex | -$54M | $3.2B |
| Gross MarginGross profit ÷ Revenue | -8.6% | +86.3% |
| Operating MarginEBIT ÷ Revenue | -12.3% | +25.7% |
| Net MarginNet income ÷ Revenue | -10.9% | +31.4% |
| FCF MarginFCF ÷ Revenue | -12.1% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +34.7% | -2.5% |
Valuation Metrics
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $188M | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $108M | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.43x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x |
| EV / EBITDAEnterprise value multiple | — | 21.64x |
| Price / SalesMarket cap ÷ Revenue | 29.13x | 7.50x |
| Price / BookPrice ÷ Book value/share | 0.93x | 2.72x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-63 for MOLN. MOLN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs MOLN's 2/9, reflecting strong financial health.
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -63.1% | +14.4% |
| ROA (TTM)Return on assets | -53.7% | +11.1% |
| ROICReturn on invested capital | -47.6% | +12.4% |
| ROCEReturn on capital employed | -36.9% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 0.09x |
| Net DebtTotal debt minus cash | -$61M | -$16.2B |
| Cash & Equiv.Liquid assets | $64M | $18.9B |
| Total DebtShort + long-term debt | $2M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | -3345.44x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $2,556 for MOLN. Over the past 12 months, REGN leads with a +12.4% total return vs MOLN's -0.1%. The 3-year compound annual growth rate (CAGR) favors REGN at 1.1% vs MOLN's -7.0% — a key indicator of consistent wealth creation.
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +19.0% | +0.8% |
| 1-Year ReturnPast 12 months | -0.1% | +12.4% |
| 3-Year ReturnCumulative with dividends | -19.6% | +3.4% |
| 5-Year ReturnCumulative with dividends | -74.4% | +69.8% |
| 10-Year ReturnCumulative with dividends | -74.4% | +104.7% |
| CAGR (3Y)Annualised 3-year return | -7.0% | +1.1% |
Risk & Volatility
MOLN is the less volatile stock with a 0.20 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.20x | 0.58x |
| 52-Week HighHighest price in past year | $5.36 | $821.11 |
| 52-Week LowLowest price in past year | $3.36 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +93.7% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 58.7 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 4K | 687K |
Analyst Outlook
Wall Street rates MOLN as "Hold" and REGN as "Buy". Consensus price targets imply 158.8% upside for MOLN (target: $13) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | MOLNMolecular Partner… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $13.00 | $857.17 |
| # AnalystsCovering analysts | 3 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 21 | Feb 26 | Change |
|---|---|---|---|
| Molecular Partners … (MOLN) | 100 | 23.26 | -76.7% |
| Regeneron Pharmaceu… (REGN) | 100 | 131.39 | +31.4% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs Molecular Partners … (MOLN)'s -74%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Molecular Partners … (MOLN) | $23M | $5M | -78.4% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Molecular Partners … (MOLN) | -80.8% | -10.9% | +86.5% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Molecular Partners … (MOLN) | -0.91 | -1.59 | -74.7% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Molecular Partners AG generated $-60M FCF in 2024 (+35% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
MOLN vs REGN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MOLN or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MOLN or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -74.4% for Molecular Partners AG (MOLN). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus MOLN's -74.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MOLN or REGN?
By beta (market sensitivity over 5 years), Molecular Partners AG (MOLN) is the lower-risk stock at 0.20β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 182% more volatile than MOLN relative to the S&P 500. On balance sheet safety, Molecular Partners AG (MOLN) carries a lower debt/equity ratio of 2% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — MOLN or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -1087.4% for Molecular Partners AG — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -1231.7% for MOLN. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is MOLN or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for MOLN: 158.8% to $13.00.
06Which pays a better dividend — MOLN or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. MOLN does not pay a meaningful dividend and should not be held primarily for income.
07Is MOLN or REGN better for a retirement portfolio?
For long-horizon retirement investors, Molecular Partners AG (MOLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.20)). Both have compounded well over 10 years (MOLN: -74.4%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MOLN and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.